TABLE 2.
Associations between GIST FGL2 expression and seven clinicopathological factors in the SSGXVIII trial patient population
| Factor | GIST FGL2 expression | p | |
|---|---|---|---|
| Negative N = 59 n (%) | Positive N = 213 n (%) | ||
| Gender | |||
| Male | 33 (24.6) | 101 (75.4) | |
| Female | 26 (18.8) | 112 (81.2) | 0.247 |
| Site | |||
| Gastric | 26 (17.6) | 122 (82.4) | |
| Nongastric | 32 (26.2) | 90 (73.8) | 0.085 |
| N.A. | 1 | 1 | |
| Tumour rupture | |||
| Yes | 10 (17.2) | 48 (82.8) | |
| No | 49 (22.9) | 165 (77.1) | 0.354 |
| KIT or PDGFRA mutation | |||
| KIT mutation | 43 (20.3) | 169 (79.7) | |
| KIT exon 11 | 41 | 150 | |
| KIT exon 9 | 1 | 16 | |
| KIT exon 13 | 1 | 3 | |
| PDGFRA mutation | 8 (25.8) | 23 (74.2) | |
| PDGFRA D842V | 5 | 18 | |
| Neither KIT nor PDGFRA mutation | 8 (36.4) | 14 (63.6) | 0.199 |
| N.A. | 0 | 7 | |
| Mitotic count (per 50 HPFs) | |||
| ≤Median (≤6/50 HPFs) | 19 (13.6) | 121 (86.4) | |
| >Median (>6/50 HPFs) | 37 (29.6) | 88 (70.4) | 0.001 |
| N.A. | 3 | 4 | |
| Median age, years (range) | 58 (22–79) | 61 (26–81) | 0.264 |
| Median tumour size, cm (range) | 11 (3–21) | 9 (2–30) | 0.009 |
Abbreviations: HPF, high‐power field of the microscope; N.A., not available.